MacroGenics to Participate in Upcoming Investor Conference
MacroGenics (NASDAQ: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's management team will engage in a fireside chat on May 8, 2025, at 10:30am ET, along with one-on-one meetings.
A webcast of the presentation will be available in the Investor Relations section of MacroGenics' website and will remain accessible for 30 days after the event.
MacroGenics (NASDAQ: MGNX), un'azienda biofarmaceutica specializzata in terapie oncologiche basate su anticorpi, ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference a New York. Il team di gestione dell'azienda parteciper脿 a una conversazione informale il 8 maggio 2025 alle 10:30 ET, oltre a incontri individuali.
Una trasmissione in diretta della presentazione sar脿 disponibile nella sezione Investor Relations del sito web di MacroGenics e rester脿 accessibile per 30 giorni dopo l'evento.
MacroGenics (NASDAQ: MGNX), una empresa biofarmac茅utica especializada en terapias oncol贸gicas basadas en anticuerpos, ha anunciado su participaci贸n en la pr贸xima Citizens Life Sciences Conference en Nueva York. El equipo directivo de la compa帽铆a participar谩 en una charla informal el 8 de mayo de 2025 a las 10:30 am ET, adem谩s de reuniones individuales.
Una transmisi贸n en l铆nea de la presentaci贸n estar谩 disponible en la secci贸n de Relaciones con Inversores del sitio web de MacroGenics y permanecer谩 accesible durante 30 d铆as despu茅s del evento.
MacroGenics (NASDAQ: MGNX)電� 頃泊 旮半皹 鞎� 旃橂鞝滊ゼ 鞝勲鞙茧 頃橂姅 氚旍澊鞓れ牅鞎� 須岇偓搿�, 雺挫殨鞐愳劀 鞐措Μ電� Citizens Life Sciences Conference鞐� 彀胳棳頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 須岇偓 瓴届榿歆勳潃 2025雲� 5鞗� 8鞚� 鞓れ爠 10鞁� 30攵� ET鞐� 歆勴枆霅橂姅 雽�頇旍嫕 韱犽鞐� 彀胳棳頃橂┌, 1:1 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
氚滍憸 鞗轨簮鞀ろ姼電� MacroGenics 鞗轨偓鞚错姼鞚� 韴瀽鞛� 甏�瓿� 靹轨厴鞐愳劀 鞝滉车霅橂┌, 頄夓偓 頉� 30鞚� 霃欖晥 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
MacroGenics (NASDAQ : MGNX), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les th茅rapies anticorps contre le cancer, a annonc茅 sa participation 脿 la prochaine Citizens Life Sciences Conference 脿 New York. L'茅quipe de direction de l'entreprise participera 脿 une discussion informelle le 8 mai 2025 脿 10h30 ET, ainsi qu'脿 des r茅unions individuelles.
Une retransmission en direct de la pr茅sentation sera disponible dans la section Relations Investisseurs du site web de MacroGenics et restera accessible pendant 30 jours apr猫s l'茅v茅nement.
MacroGenics (NASDAQ: MGNX), ein biopharmazeutisches Unternehmen, das sich auf antik枚rperbasierte Krebstherapeutika spezialisiert hat, hat seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference in New York angek眉ndigt. Das Management-Team des Unternehmens wird sich am 8. Mai 2025 um 10:30 Uhr ET an einem Gespr盲ch am Kamin beteiligen und Einzelgespr盲che f眉hren.
Ein Webcast der Pr盲sentation wird im Bereich Investor Relations auf der Website von MacroGenics verf眉gbar sein und ist 30 Tage nach der Veranstaltung abrufbar.
- None.
- None.
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month:
- The Citizens Life Sciences Conference (New York). Members of MacroGenics鈥� management team will participate in a fireside chat on Thursday, May 8, 2025, at 10:30am ET. Management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at . The Company will maintain an archived replay of the webcast on its website for 30 days.
About聽MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of
MacroGenics, Inc.
Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 [email protected] Argot Partners 1-212-600-1902 [email protected]
FAQ
When is MacroGenics (MGNX) presenting at the Citizens Life Sciences Conference 2025?
Where can I watch MacroGenics' (MGNX) presentation at the Citizens Life Sciences Conference?
What type of meetings will MacroGenics (MGNX) management participate in at the Citizens Life Sciences Conference?
What is MacroGenics' (MGNX) main business focus?
